Edition:
India

Ludwig Burger

RPT-INSIGHT-Decades of work, and half a dose of fortune, drove Oxford vaccine success

24 Nov 2020

* Pandemic gave Oxford the chance to show vaccine technique worked

Decades of work, and half a dose of fortune, drove Oxford vaccine success

24 Nov 2020

LONDON/FRANKFURT It took Oxford University's brightest minds decades of work to give them the expertise to develop a COVID-19 vaccine. In the end, it was a momentary error - and a dose of good fortune - that carried them over the line.

Decades of work, and half a dose of fortune, drove Oxford vaccine success

24 Nov 2020

LONDON/FRANKFURT It took Oxford University's brightest minds decades of work to give them the expertise to develop a COVID-19 vaccine. In the end, it was a momentary error - and a dose of good fortune - that carried them over the line.

Dosing error turns into lucky punch for AstraZeneca and Oxford

23 Nov 2020

FRANKFURT/LONDON A stroke of good fortune from a dosing error will pave the way for AstraZeneca and Oxford University to submit their COVID-19 vaccine for regulatory clearance.

Dosing error turns into lucky punch for AstraZeneca and Oxford

23 Nov 2020

FRANKFURT/LONDON A stroke of good fortune from a dosing error will pave the way for AstraZeneca and Oxford University to submit their COVID-19 vaccine for regulatory clearance.

Dosing error turns into lucky punch for AstraZeneca and Oxford

23 Nov 2020

FRANKFURT/LONDON A stroke of good fortune from a dosing error will pave the way for AstraZeneca and Oxford University to submit their COVID-19 vaccine for regulatory clearance.

Dosing error turns into lucky punch for AstraZeneca and Oxford

23 Nov 2020

FRANKFURT/LONDON A stroke of good fortune from a dosing error will pave the way for AstraZeneca and Oxford University to submit their COVID-19 vaccine for regulatory clearance.

Pfizer-BioNTech vaccine deliveries could start 'before Christmas'

19 Nov 2020

Pfizer Inc and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday. | Video

BioNTech says vaccine approval possible in mid-December under ideal conditions

19 Nov 2020

FRANKFURT U.S. and European regulators could approve Pfizer and BioNTech's experimental COVID-19 vaccine as early as mid-December, the German firm's chief executive said on Wednesday, following the release of positive trial results. | Video

Analysis: Can first COVID-19 vaccines bring herd immunity? Experts have doubts

19 Nov 2020

FRANKFURT/LONDON Governments and officials are voicing hopes that COVID-19 vaccines could bring "herd immunity", with some calculating that immunising just two-thirds of a population could halt the pandemic disease and help protect whole communities or nations. | Video

World News